Literature DB >> 588802

Comparative evaluation of the in vitro effects of hydralazine and hydralazine acetonide on arterial smooth muscle.

K Barron, O Carrier, K D Haegele, A J McLean, J L McNay, P Du Souich.   

Abstract

1. Dose-response relationships to K+ were determined in isolated strips of rabbit aorta. 2. K+ contractures were induced by 30 mM K+ in paired strips from individual animals. The effects of hydralazine and hydralazine acetone hydrazone (hydralazine acetonide) on these contractures were studied. 3. Hydralazine and hydralazine acetonide both produced dose-dependent decreases of K+-induced tone. Threshold concentrations for hydralazine were 11.89 +/- 4.5 X 10(-5) M (mean +/- s.d.) and for hydralazine actonide 9.7 +/- 4.6 X 10(-5) M (0.5 less than P less than 0.4). 4. The magnitude of the effect of hydralazine acetonide was greater than that of hydralazine at all concentrations above threshold, as reflected in a significant difference (P less than 0.05) in the slopes of dose-response curves to the two treatments. The vasodilator effects of hydralazine and the acetonide were terminated by washout of the bath. 5. The differences in effect were not due to instability of hydralazine under in vitro conditions. 6. It is concluded that hydralazine acetonide has intrinsic activity on vascular smooth muscle which differs significantly from that of the parent compound and that this may contribute to the hypotensive effects which follow administration of the parent compound.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 588802      PMCID: PMC1667883          DOI: 10.1111/j.1476-5381.1977.tb08426.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Distribution of hydralazine-1-C-14 after injection into normal mice.

Authors:  H M PERRY; P COMENS; A YUNICE
Journal:  J Lab Clin Med       Date:  1962-03

2.  Determination of hydralazine and its metabolites by gas chromatography-mass spectrometry.

Authors:  K D Haegele; H B Skrdlant; N W Robie; D Lalka; J L McNay
Journal:  J Chromatogr       Date:  1976-11-03

Review 3.  Medical intelligence drug therapy.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1976-08-05       Impact factor: 91.245

Review 4.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

5.  Duration of hydralazine action in hypertension.

Authors:  K O'Malley; J L Segal; Z H Israili; M Boles; J L McNay; P G Dayton
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

6.  Metabolism and disposition of hydralazine-14C in man and dog.

Authors:  J M Lesser; Z H Israili; D C Davis; P G Dayton
Journal:  Drug Metab Dispos       Date:  1974 Jul-Aug       Impact factor: 3.922

7.  Radioautographic localization of hydralazine-1-C-14 in arterial walls.

Authors:  D Moore-Jones; H M Perry
Journal:  Proc Soc Exp Biol Med       Date:  1966-06
  7 in total
  4 in total

Review 1.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

2.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

3.  Identification of hydrallazine and hydrallazine hydrazone metabolites in human body fluids and quantitative in vitro comparisons of their smooth muscle relaxant activity.

Authors:  K D Haegele; A J McLean; P du Souich; K Barron; J Laquer; J L McNay; O Carrier
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

4.  Inhibition of calcium release from the sarcoplasmic reticulum of rabbit aorta by hydralazine.

Authors:  A M Gurney; M Allam
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.